Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in late primary spermatocytes | 0.75 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6059
Sealed predictions
- BBS5 in dopamine neurons, braak+0.09 (p 0.820) → -0.20 (p 0.607)receipt 6066
Swarm cases
receipt 6066: BBS5 in dopamine neurons, braak
- power
- full sample -0.04 (p 0.867, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.00 (p 0.990, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.787, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.05, sign flips 4; without severely affected donors -0.04 (p 0.867, n 18). fragile.
- cell type
- strongest in astrocytes: -0.68 (p 0.0018, n 18) vs -0.04 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BBS5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up BBS5 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.30 p 0.286 (needs p < 3.3e-4)
Receipts
loading the receipts